Early home return for patients after prostate adenoma surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a new rehabilitation care pathway aimed at reducing the hospitalization duration for patients undergoing endoscopic enucleation of prostate adenoma using laser technology. Traditionally, patients are hospitalized for at least 48 hours, but this approach seeks to allow discharge within 24 hours while ensuring patient safety through supervised home care by nurses. The study hypothesizes that this model can be effectively implemented in other healthcare settings without increasing the risk of complications. The intervention focuses on improving patient involvement in their care and enhancing the overall recovery process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient planned for endoscopic enucleation of prostate adenoma with laser
* Patient with symptomatic benign prostatic hyperplasia and refractory to medical reatment and/or
* Patient with benign prostatic hyperplasia complicated by chronic retention of urine and/or
* Patient with benign prostatic hyperplasia complicated by prostatitis and/or
* Patient with symptomatic benign prostatic hyperplasia

Exclusion Criteria:

* Patient living beyond the scope of care by the nurses coordination
* Bedridden patient or WHO clinical condition \>2
* Patient requiring curative anticoagulation which cannot be interrupted or relayed at home by heparin
* Patient with double anti-platelet aggregation who cannot be interrupted

Where it's running

• Clinique de l'Union
  Saint-Jean, France Recruiting

Study contacts

• Principal investigator: Philippe ROUVELLAT, MD — Gcs Ramsay Sante
• Study coordinator: Philippe ROUVELLAT, MD
• Email: r.rouvellat.union@gmail.com
• Phone: + 33 5 61 37 82 93

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• gdFTRD System Registry for Gastroduodenal Full-Thickness Resection

  This registry tests how the gdFTRD device is used in real-world care for adults with subepithelial tumors or epithelial neoplasia in the stomach or duodenum to see what outcomes and complications appear.

  Recruiting at 2 sites Ovesco Endoscopy AG · Freiburg im Breisgau, Germany and 2 other locations · NCT07142902

• R-5780 with PD-1 blockers for adults with advanced melanoma and other solid tumors

  This Phase 1 test will try an oral probiotic called R-5780 together with PD-1 checkpoint inhibitors to see if adults with advanced solid tumors can tolerate it safely.

  Recruiting at 2 sites Phase 1 Rise Therapeutics LLC · Denver, Colorado and 1 other locations · NCT06398418

• Multi-omics approach for early detection of colorectal cancer

  This study is testing a new way to spot colorectal cancer early by looking at blood samples from people with cancer and healthy individuals to see if certain markers can help predict the disease.

  Recruiting at 6 sites Zhejiang University · Hangzhou, Zhejiang and 5 other locations · NCT06220617

• Proton therapy for brain tumors

  This study is testing whether proton therapy can be a better treatment option for patients with certain brain tumors by comparing it to traditional radiation methods to see if it can reduce harm to healthy tissues.

  Recruiting at 3 sites Maastricht Radiation Oncology · Maastricht, Limburg and 2 other locations · NCT04648462

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.